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1.	  Background	  and	  Literature	  Review	  
1.1	  Diabetes	  Mellitus	  as	  a	  metabolic	  disorder	  
 
Type 2 Diabetes Mellitus (DM2) is a metabolic disorder that is associated with 
defects in insulin utilization. DM2 is very prevalent in the adult population 
affecting approximately 29.1 million people in the US alone, which is roughly 
9.3% of the population [1]. DM2 affects patients by increasing the risk to 
macrovascular and microvascular complications such as stroke, coronary artery 
disease, neuropathy and seem to affect long bones as well [2]. It is considered a 
risk factor for dental implant complications [3]. These alterations may impair 
response to surgical trauma in patients with inadequate diabetic control [4,5]. In 
order to assess ones diabetic levels, glycosylated hemoglobin levels (HbA1c) are 
utilized as surrogates for the assessment of diabetic control during pre-surgical 
treatment planning in the medical field [5,6]. According to the American 
Diabetes Association, well controlled individuals have an HbA1c ≤ 5.7% while 
pre-diabetes ranges from 5.7-6.4% and individuals diagnosed with diabetes 
includes HbA1c values of 6.5% and higher. DM2 had been associated with high 
bone mineral density and also higher bone fracture rates when compared with 
non diabetic individuals [7].  
2	  	  
 
According to multiple studies, high glucose levels may lead to accumulation of 
Advanced Glycosylation End Products in the organic bone which may lead to 
collagen production distortion that could result in a more fragile bone formation 
[8]. The most frequently encountered complications in implant dentistry in 
patients with poor diabetic control are soft tissue associated [4,9]. 
 
1.2	  Previously	  published	  evidence	  on	  Type	  II	  DM	  bone	  
histomorphometry	  
 
Klein et al. [10] in the early 1960s, was the first to report a histomorphometrical 
analysis on bone in patients with Type II DM. They noted an increase cortical 
surface area in the rib bone. Conversely, multiple authors subsequently found a 
decrease in bone formation depicted by a decrease in mineral apposition and rate 
of bone formation suggesting that Type II DM promote osteoblastic activity 
dysfunction [11,12]. Manavalan et al. [13] investigated iliac crest bone biopsies 
from six Type II DM postmenopausal women and found reduced osteoid, 
osteoblast and mineralizing surfaces when compared to iliac crest biopsies from 
six non-diabetic postmenopausal women.  
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1.3	  The	  role	  of	  Advanced	  Glycation	  End	  Products	  	  
 
While bone mineral density is the determinant of bone strength, the collagen 
fibers are the major contributors for tensile strength, ductility and toughness [14]. 
Among the influencing factors affecting these properties are the tissue turnover 
rate and the cellular activity. Collagen cross-link formation can be classified into 
either lysyl oxidase regulated or oxidation induced Advanced Glycation End 
Products (AGEs) cross-linking. Saito and Marumo reported that increased AGEs 
levels lead to poor bone quality formation with increased risk of fracture [15]. 
AGEs relate to increased osteoclastic activity in postmenopausal patients with 
osteoporosis [16, 17]. Valcourt et al, have found that AGEs decrease bone 
resorption by altering the structural integrity of bone matrix protein while also 
inhibiting osteoclastic differentiation [18]. AGEs tissue levels seems to be 
regulated by glycemic control, oxidative stress and the tissue’s life span 
[19,20,21]. The onset of Type II DM is accompanied by a marked increase of 
AGEs as well as a decrease in bone quality associated with minimal change to 
collagen content and bone mineral density [2]. Consequently, it can be concluded 
from the preceding literature that AGEs are associated with low-bone formation 
and turnover [23]. 
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1.4	  Present	  histological	  data	  
 
La Fontaine et al. [24] histologically evaluated bone biopsies from feet and 
ankles of non-diabetic and Type II DM patients. They found that the diabetic 
group formed mostly lamellar bone, with less osteocytes when compared to the 
non-diabetic group. A few lacunae were empty and the marrow spaces were 
filled with adipose tissue. The trabeculae in the diabetic group were thinner and 
fewer. Minimal bone remodeling was present and fewer osteoblasts were present. 
They concluded that the diabetic group displayed less overall cellularity which 
might impair the reparative process.  
 
1.5	  Changes	  to	  bone	  microstructure	  
 
Type II DM has been associated with increased mineralization of  cancellous 
bone as well as with increased cortical porosity [23,25,26]. The severity of this 
cortical porosity seems to be associated with the extent and duration of the 
diabetic disease.  
However, newly diagnosed individuals presented with a similar risk of bone 
fracture risk as healthy individuals [27,28]. It has been well established that 
circulating osteogenic precursor cells are down regulated in Type II DM while 
mesenchymal stem cells are more likely to differentiate to adipocytes, yielding 
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an increase bone marrow adiposity in Type II DM patients when compared to 
healthy control subjects.  [13,29,30].  
 
1.6	  Diabetes	  Mellitus	  and	  Possible	  Post	  Surgical	  
Complications	  
 
A large retrospective study of total joint replacement retrospectively evaluated 
the results of 6,088 hip replacement surgeries in diabetic patients that presented 
with increased HbA1c levels [31]. It was found that when comparing different 
HbA1c level thresholds, a decrease from 7.5% to 6.5% resulted in a small 2.7% 
reduction in post-surgical complications but was associated with 18.8% 
unnecessary delays in an attempt to achieve better glycemic control. Tawil et al. 
investigated the effects of Type II DM on dental implant survival and the 
associated complications in 90 patients. It was concluded that an 8% rate of soft 
tissue complications was observed in patients with HbA1c values between 7% 
and 9% when compared to a rate of 6% in patients with HbA1c levels less than 
7% [32]. Another study by Oates et al. reported that individuals with HbA1c 
levels ≥ 8.1% exhibited compromised early implant stability [3]. However, other 
published studies have not consistently shown significantly compromised 
survival rates in poorly controlled diabetics [4,32,33,34]. 
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1.7	  Diabetes	  Mellitus	  and	  Dental	  Implants	  
 
Therapeutic management of DM2 has been based upon the regulation of elevated 
levels of hyperglycemia. Significant evidence exists to support the placement of 
implants in diabetics with HbA1c levels within the normoglycemic range 
[3,4,33,35]. However, recent publications of clinical trials have addressed the 
success of implants placed inn patients with poorly controlled diabetes. The 
harmful effects of hyperglycemia on implant integration and survival has been 
attributed to microvascular complications in the alveolar bone that lead to 
compromised blood supply and decreased bone density [36]. Nonetheless, 
patients with DM2 that cannot achieve optimal glycemic control (HbA1c<7.0%) 
may represent over 50% of the diabetic patient population [37]. Thus, the 
histological identification of variations in bone vascularity and morphology may 
improve the efficacy of  implant treatment modalities in this patient group 
thereby increasing the Oral Health Related Quality of Life for this large portion 
of the population.  
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1.8	  SLA	  active	  implant	  characteristics	  
 
Variations in implant surface texture and composition have been developed to 
enable poorly controlled diabetics to gain access to implant care while 
minimizing post operative complications, researchers have identified improved 
implant characteristics that can enhance implant osseointegration in pre-clinical 
studies performed with diabetic animal models. Chemically modified, micro-
rough, hydrophilic (SLActive®) titanium implant surfaces have been shown to 
promote bone formation and accelerate osseointegration of dental implants 
placed in diabetic animals [9,38]. It was noted that these implants promote 
angiogenesis and that the increased angiogenesis is directly correlated with new 
bone formation [39]. It has been hypothesized that this enhanced biologic 
response is due to the biocompatibility and hydrophilicty of the surface that 
actively attracts blood and becomes populated by progenitor cells and growth 
factors that improve stromal cell differentiation [40]. A recent advancement of 
this chemically modified surface is the introduction of a binary Titanium-
Zirconium (TiZr) alloy that is compatible with the SLActive surface treatment 
[41]. In vitro pre-clinical studies have shown that hydrophilic TiZr implants 
(Roxolid®) have a dual benefit over titanium implants with SLActive modified 
surfaces. TiZr implants have a higher tensile strength that enables use of narrow 
diameter implants without risk of implant body fracture. These implants also 
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enhance bone in-growth compared to chemically modified titanium surfaces 
[41,42].  
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2.	  Rationale,	  Hypothesis	  and	  Specific	  Aims	  
 
2.1	  Rationale	  
 
Pre-clinical studies support the use of hydrophilic TiZr implants (Roxolid®). It 
has been speculated that the more hydrophilicty an implant surface is may lead to 
greater vascularity during the implant integration period with enhancement in 
growth of bone on the implant surface as previously shown in animal studied 
[9,38]. Consequently, the use of the hydrophilic TiZr implant surface could 
enhance implant placement in poorly controlled diabetic patients and help 
alleviate disparities in oral health-related quality of care issues among diabetic 
patients.  
 
2.2	  Hypothesis	  
 
Hyperglycemia results in compromise vascularity and increased bone marrow 
adiposity in the mandibular bone. Therefore, hydrophilic TiZr implant surfaces 
(Roxolid®) that actively attract fluids and possess excellent osteoconductive 
properties leads to an early implant survival and success in poorly controlled 
DM2 patients to levels comparable to well-controlled DM2 patients.  
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2.3	  Primary	  objective	  
 
Assess bone vascularity and bone marrow adiposity in well controlled diabetic 
patients versus poorly controlled diabetic patients by means of 
histomorphometric and immunohistochemical assessments. 
 
2.4	  Secondary	  objective	  
 
The secondary objective of this study is to compare in well-controlled DM2 
patients versus poorly-controlled DM2 the initial implant stability of hydrophilic 
TiZr implant surfaces (Roxolid®), post-surgical pain levels, early implant 
survival and success rates at three years.  
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3.	  Material	  and	  Methods	  
 
3.1	  Study	  population	  
 
The study population consisted of partially edentulous adults enrolled as well 
controlled type 2 diabetic patients (5.8<HbA1c≤7.0%) and poorly controlled 
type 2 diabetics (7.5<HbA1c<10%). Participants were recruited from patients 
with a diagnosis of Type II Diabetes Mellitus and presented to the Advanced 
Education Program in the Division of Periodontology at the University of 
Minnesota for implant treatment in the mandible. Participants who met the 
following inclusion and exclusion criteria were accepted into the study. 
 
Inclusion criteria: 
• Adult patients aged 18-85 years with a physician diagnosed DM2. 
• History of DM2 for at least two years prior to enrollment.  
• At least one edentulous site in the mandibular canine or posterior mandible regions. 
• HbA1c >7.5% & <10% for enrollment in the test group.  
• HbA1c >5.8% & ≤7.0% for enrollment in the control group. 
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Exclusion criteria: 
•       Mandibular sites that will not allow bone core retrieval due to limited   
      alveolar bone width (ridge width <6mm, height <12mm) as confirmed by 
pre- 
 operative Cone Beam Computed Topography (CBCT). 
• Smokers: current, or ex-smokers with <2 years since smoking cessation. 
• Patients that present with a grafted study site. 
• Active periodontal disease that is not in remission.  
• Medications that affect bone healing (e.g. bisphosphonates or chronic steroids). 
• Patients who are carriers of transmissible disease(s) that may unnecessarily 
            expose laboratory personnel to risks such as HIV, Hepatitis C and others.  
•       Participants with a physician diagnosis of osteoporosis (Z-score ≤ -2).  
• Females during pregnancy or lactation and females that plan to become pregnant 
within the following year. 
• Patients that will not agree to participate in this study or sign the consent form. 
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3.2	  IRB	  approval	  
 
Initial University of Minnesota Institutional Review Board approval was 
received on May 21st, 2015.  
 
3.3	  Straumann	  LTD	  support	  
 
Application to Straumann LTD for research support was submitted in December 
2014 and approved by Straumann LTD on February 27th, 2015. A total of 46 
Roxolid SLActive® implants (Forty-two 4.1 mm x10 mm & Four 4.1 mm x8 
mm) with 48 healing abutments (varying sizes) were provided by Straumann 
LTD for this investigation.  
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3.4	  Patient	  appointments	  
 
3.4.1	  Pre	  operative	  consult	  appointment	  
 
School of Dentistry patients who met the inclusion criteria were contacted via 
phone or in person to ask if they would be willing to volunteer to become a 
participant in this study. Information about their medical and dental history was 
obtained from a complete dental and periodontal examination. Any necessary 
dental treatment was completed prior to official enrollment into the study. All 
patients were asked to undergo a baseline CBCT radiographic examination of the 
mandible to ensure the presence of adequate bone width and height. The CBCT 
was analyzed by a board certified oral radiologist, Dr. Mansur Ahmad, DDS, 
PhD and by the operating surgeon [43]. A blood draw was performed and 
submitted to a CLIA-certified lab (Fairview Diagnostic Laboratories, 420 
Delaware ST SE, Minneapolis MN, 55455) to confirm that the HbA1c values 
were within the above mentioned inclusion range. Blood was drawn from the 
antecubital fossa and transferred into a 3mL EDTA coated tube (Fisher 
Scientific, Pittsburg, PA, USA).  
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3.4.2.1	  Implant	  surgical	  visit	  
 
Eligible patients, who met the inclusion and exclusion criteria were invited to 
participate in this clinical trial. A consent form and a Health Insurance 
Portability and Accountability (HIPAA) form were given and verbally read to 
each patient. Upon signing the consent form, blood pressure was taken, patients 
were pre-medicated with 1 gram amoxicillin. If, a patient was allergic to the 
penicillin group of antibiotics then a 300 mg dose of clindamycin was given 
instead. A 0.12% chlorhexidine gluconate intra-oral rinse was given for 1 minute 
prior to the start of the surgery. Patients were prepared according to the sterile 
protocol provided by Scharf et al. that included sterile gloves, implant, 
instruments, irrigation, gowns, drapes and masks, antibiotic coverage, head 
covers and peri-oral skin preparation [44]. Routinely, 2% Lidocaine with 
1:100,000 epinephrine (Dentsply Pharmaceuticals, Cambridge, Ontario, Canada) 
was used for inferior alveolar nerve block in the operated quadrant. After giving 
anesthesia, a mid-crestal incision was performed with either a 12b or 15c scalpel 
followed by a full thickness mucoperiosteal  flap reflection. If that flap reflection 
did not provide sufficient visibility a vertical releasing incision was placed on the 
buccal surface. The osteotomy site was identified with the help of the restorative 
dentist (Dr. E. Johnson, DDS) and was marked with a ½ round carbide bur in a 
16	  	  
slow speed handpiece utilizing copious sterile saline irrigation. A two-piece 2.75 
mm internal diameter and 3.5 mm external diameter trephine surgical bur was 
employed at 300 rpms under continuous sterile saline irrigation was used to 
retrieve a bone core (2.5x7.0 mm) from the future implant site (Figure 1).  
17	  	  
The retrieved bone core would of otherwise been removed during implant site 
preparation and discarded as surgical waste. The bone core was immediately 
transferred to a 10% neutral buffered formalin for 12 hours and later to 70% 
ethanol. Bone core samples were then sent for analysis to the University of 
Minnesota Masonic Cancer Center, St. Paul, Minnesota (Dr. O’Sullivan). Further 
preparation of the surgical area continued per Straumann LTD protocol, which 
included preparation with a final twist drill (Twist Drill PRO, 3.5Ø) at 500 rpms 
under copious sterile saline irrigation. If needed, a Straumann Bone Level Tap 
Drill was utilized (For D-1 bone) at 15 rpms. All participants of this study 
received a single 4.1x10 mm Titanium-Zirconia, hydrophilic (Roxolid®) 
implant. The maximum insertion torque was recorded using the implant 
handpiece and confirmed by the hand torque wrench. The implant stability 
quotient (ISQ) was measured in two planes (Mesial and Buccal) three times and 
the average was recorded as an index of primary implant stability [45]. Any 
exposed threads were measured, recorded and bone grafted if necessary. The 
healing abutment was connected to the implant unless otherwise contraindicated 
by a low insertion torque (<15 N.cm). Routine interrupted Coated Vicryl 4-0 
sutures were placed (Ethicon, Somerville NJ, USA) to allow for passive flap 
closure.  
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3.4.2.2	  Post-­‐operative	  care	  
 
Patients undergoing implant placement in the Advanced Education in 
Periodontology Clinic at the University of Minnesota School of Dentistry 
received routine post operative-instructions verbally and in written form. Ice was 
applied to the surgical side for the first several hours after surgery to minimize 
swelling. Post-operative analgesic consisted of 600mg of Ibuprofen 4 times a day 
for the first 3 days and then as needed for pain management. Chlorhexidine 
gluconate (0.12%) rinses were performed by the patient twice a day for 14 days. 
Following the initial pre-operative loading dose of 1,000mg of Amoxicillin a 
dosage of 500 mg was prescribed for three times a day for 7 days. Patients who 
were allergic to the penicillin family of antibiotic were prescribed with 
clindamycin 150 mg three times a day for 7 days. Patients were instructed to 
avoid brushing the surgical site and to chew on the opposite side of their mouth 
during the healing period. 
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3.4.3	  One	  and	  Two	  week	  post-­‐operative	  visits	  
 
Patients were seen at 1 and 2 week post-operative visits whereby adverse events 
were recorded. Two separate registries of surgery-related adverse events (AE) 
regarding known surgical risks (e.g. wound infection [defined as surgical sites 
presenting with active exudate] or sites with an implant failure [with evidence of 
an implant rejection]), and unanticipated serious adverse events (SAE) [defined 
as intraoral and or extraoral swelling, osteomyelitis or cellulitis] were noted and 
managed. Self reported pain on a 0-10 visual analog scale (VAS) was recorded 
with 0 being no pain and 10 being the most intensive pain experienced. 
Periapical radiographs were taken with customized Eggen holders for each 
patient to assess peri-implant bone levels at the second visit and at subsequent 
observation visits, according to Kotsakis et al. [45]. The customized bite 
registration material was disinfected and stored with the patient’s study 
registration marked with a 5-digit ID code for use at subsequent evaluations 
evaluations. Blood specimen to determine soluble RANKL/OPG ratio 
(sRANKL/OPG) were drawn from the antecubical fossa in the second week.  
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3.4.4	  Four	  and	  Eight	  week	  post-­‐operative	  visits	  
 
Patients were seen at Four and Eight weeks post-surgeru for AE and SAE 
registration, self-report VAS (0-10 scale) and blood work for sRANKL/OPG. 
 
3.4.5	  Three	  month	  post	  implant	  placement	  visit	  
 
At three months following implant placement the implants were assessed for 
successful clinical integration according to the criteria established by Karoussis 
et al. [46]. In addition, Implant Stability Quotient (ISQ) values (Osstell ISQ ® 
Integration Diagnostics, Goteborg, Sweden) were evaluated. ISQ is an indirect 
measurement of the implant micro mobility, the metal rod (sensor) is connected 
to the inserted implant is subjected to 1N lateral load 10mm above the bone 
level, the sensor is subjected to magnetic pulses. High implant stability results in 
more sensor vibrations and higher ISQ values. ISQ values range from 0-100, 0-
60 is considered to be low stability, 60-70 medium stability and 70+ high 
stability. The clinical significance of the ISQ values were described by Nedir et 
al, which found that an ISQ values of 54 predicted 100% osseointegration for 
immediately placed implants. The same group also recommended delayed 
loading when the ISQ values were <49 [53].  
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Karoussis et al. successful implant integration criteria consists of: 
1. Absence of mobility 
2. Absence of persistent subjective complaints (pain, foreign body sensation and or 
dysesthesia) 
3. Probing depth (PD) ≤5mm 
4. No PD≥5 and Bleeding on Probing (BOP) positive sites 
5. Absence of continuous radiolucency around the implant 
6. After the first year of service, the annual bone loss should not exceed 0.2 mm. 
  
Successfully integrated implants were subsequently loaded with a fixed 
prostheses [46]. A periapical radiograph was taken with the previously fabricated 
customized Eggen holder and a blood draw for HbA1c level monitoring was also 
obtained at the 3 month post implant placement visit. 
22	  	  
 
3.4.6	  Restorative	  appointments	  
 
A digital impression of the integrated implants were taken using an intraoral 
scanner (Cerec Omnicam, Sirona Dental Systems LLC, Charlotte, NC, USA). 
The scan was transferred to an authorized straumann LTD laboratory (Minnesota 
Dental Lab, St. Paul, Minnesota, USA) for the fabrication of a titanium abutment 
and a full contour zirconia crown. The custom titanium abutment was tried in 
and a bite-wing radiograph was taken to confirm complete seating. The full 
contour zirconia crown was then inserted and adjusted until balanced proximal 
contacts were achieved with dental floss that snapped but did not shred. 
Shimstock occlusal paper was then slid over the implant crown to ensure it was 
held in place by the adjacent dentition. Lastly, all excursive contacts were 
eliminated. The custom titanium abutment was torqued to 35 N.cm with a 
Straumann torque wrench. A cotton pellet was inserted into the screw hole. The 
zirconia crown was then cemented with a thin layer of RelyX lutting cement (3M 
Espe Dental Products, St. Paul, MN, USA), for 3 minutes before all excess 
cement was removed. The proximal and occlusal contacts were rechecked and 
adjusted if necessary. A final bite-wing radiograph of the implant, abutment and 
crown was then taken.  
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3.4.7	  Three	  and	  Six	  month	  post-­‐loading	  visits	  
 
Patients were evaluated for clinical implant integration and early implant 
survival at three and six months post-loading using the criteria of Karoussis et al. 
[46] The examination included assessments of implant mobility, peri-implant 
inflammation, bone loss and pain evaluation. Periapical radiographs were taken 
with customized Eggen holders to assess implant crestal bone loss for each 
implant. 
 
3.4.8	  One	  and	  Three	  year	  post-­‐loading	  follow-­‐up	  visits	  
 
At 1-year and 3-years post-loading follow-up visits, periapical radiographs will 
be taken with customized Eggen holders for routine implant monitoring and will 
be evaluated to assess crestal bone loss for each implant. Peri-implant charting 
and HbA1c levels measurements will also be obtained.  
24	  	  
 
3.5	  Core	  histology	  
3.5.1	  General	  fixation	  
 
The retrieved bone core was immediately placed in 10% formalin for overnight 
fixation. The core was washed three times in sterile saline to remove any residual 
formalin and placed in a secured vial with 70% ethanol before being transferred 
to the Masonic Cancer Center (St. Paul, Minnesota, USA) for additional 
processing. After decalcification in 10% Ethylenediaminetetraacetic acid 
(EDTA) for a few days the bone cores were dried with increasing percentages of 
ethanol washes (80%, 95%, 100%) for 35 minutes. Each ethanol wash was 
repeated twice. The bone cores were then transferred to xylene and later into hot 
paraffin using the Tissue Tek VIP (Tissue processor Sakura	  Finetek USA Inc, 
Torrance CA, USA) processor. Paraffin embedded bone cores were cut into 4-5 
µm thicknesses using a microtome. The specimen was then fixed on a slide 
overnight at 37°C.  
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3.5.2	  Hematoxylin	  and	  Eosin	  Staining	  &	  
immunohistochemistry	  using	  Factor	  VIII	  
3.5.2.1	  Preparation	  for	  staining	  
 
Bone core tissue sections were rehydrated in Xylene 3 times for 3 minutes each 
and later submerged in 100% ethanol twice for 1 minute each followed by 95% 
ethanol twice for 1 minute each and 70% ethanol once for 1 minute. The cut 
tissue sections were then washed under running tap water for 3 minutes for 
rehydration.  
 
3.5.2.2	  Hematoxylin	  staining	  
 
Hematoxylin (Harris Modified Hematoxylin with Acetic acid SH26-4D Fisher 
Scientific, Pittsburg, PA, USA) was applied for 3 minutes to the cut tissue 
sections prior to rinsing under running tap water for 3 minutes followed by a was 
with acid water (1.35 ml HCL + 900 ml distilled water) and finally running tap 
water again for 3 minutes. The core was placed in ammonium water (5 ml 
NH4OH + 175 ml Deuterium-Depleted water) for 15s and then in running tap 
water for 3 minutes to reach the desired intensity of the hematoxylin staining for 
cell nuclei labeling.  
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3.5.2.3	  Eosin	  staining	  
 
Eosin (Surgipath, Buffalo Grove, IL, USA) was applied for 30 seconds for 
cytoplasm protein staining, followed by 95% ethanol twice for 30 seconds each 
and 100% ethanol twice for 30 seconds each. The cut tissue sections were 
submerged in Xylene 3 times for 30 seconds each. Finally, a drop of Permount 
(Fisher Scientific, Pittsburg, PA, USA) clearing mounting media was placed on 
the top of the sample and covered with a cover slip.  
 
3.5.3	  Immunohistochemistry	  
3.5.3.1	  Preparation	  for	  staining	  	  
 
Bone core tissue sections were rehydrated in Xylene 3 times for 3 minutes each 
and later submerged in 100% ethanol twice for 1 minute each followed by 95% 
ethanol twice for 1 minute each and 70% ethanol once for 1 minute. The cut 
tissue sections were then washed under running tap water for 3 minutes for 
rehydration.  
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3.5.3.2	  Indirect	  Immunohistochemistry	  
 
After paraffin removal and tissue rehydration, slides were placed in Tris-buffered 
saline (TBS-T) for 1 minute. Three percent hydrogen peroxide (H2O2) was used 
activity for 15 minutes at room temperature to block endogenous peroxidase. 
Samples were washed three times using TBS-T buffer at 2 minute intervals. In 
order to remove formalin fixation and enable the antigen to be more accessible 
for the primary antibody, enzymes were removed using pre-diluted Proteinase K 
for 5 minutes followed by 3 washes of TBS-T buffer. Undiluted protein block 
(Dako Protein Block Serum-Free X0909 Dako Corp. Carpinteria, CA, USA) was 
used to inhibit non-specific staining during Immunohistochemistry (IHC) for 
antigen detection. The protein block was applied to each slide for 15 minutes and 
the slides were then drained and wiped but not rinsed.  
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3.5.3.3	  Primary	  antibody	  
 
Rabbit anti-human Von Willebrand Factor VIII (Dakot Corp, Carpinteria, CA, 
USA) was used with optimal dilution of 1:400 in Dako antibody diluent (Dako 
Corp. Capinteria, CA, USA) to label plasma glycoproteins and visualize blood 
vessels in the bone core tissue. For the negative control slides, the primary 
antibody was substituted with super sensitive rabbit negative control (BioGenex. 
Fremont, CA, USA). Slides were then incubated at room temperature for 60 
minutes. Subsequently the slides then underwent three washes of TBS-T buffer 
at 2 minute intervals. 
Antibodies were detected using undiluted Rabbit Envision+ (Dako Corp, 
Carpinteria, CA, USA) for 30 minutes at room temperature. The slides were then 
washed with TBS-T buffer at 2 minute intervals.  
 
3.5.3.4	  Chromogen	  Substrate	  
 
Sections were developed using a Diaminobenzidine (DAB) (Dako LSAB kit, 
K3468, Dakot Corp, Carpinteria, CA, USA). One drop of DAB was used per one 
ml of DAB dilution buffer. DAB was developed for 5 minutes and the slides 
were washed in running distilled water for 5 minutes.  
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3.5.3.5	  Counterstaining	  	  
 
The slides were placed in Mayer’s Hematoxylin solution (CS700, Dako Corp. 
Carpinteria, CA, USA) for 15 seconds for counterstaining and then washing in 
running distilled water for 5 minutes. Slides were then dehydrated through 
graded ethanol washes for 30 seconds; 70% once, 95% once and 100% three 
times. The slides were run through xylene for three times at 30 seconds each, a 
coverslip was placed over the slides before adding Permount for microscopic 
examination.  
 
3.6	  Bone	  core	  histology	  measurement	  	  
Due to a potential impact of the bone dust in the calculation of bone marrow 
areas and the estimation of vessel area and the vessel numbers, bone dust surface 
area was identified and calculated as a percentage of the total surface of the 
histological immunohistochemical section stained with Factor VIII. from each 
sample excluding the bone dust in the surrounding periphery. That bone dust 
percentage in each sample was used to calculate the bone marrow surface area, 
area of tissue, blood vessel surface area, percent of blood vessels surface area, 
number of blood vessels per sample and number of blood vessels per mm² per 
sample as depicted in Table 15.	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3.7	  Statistical	  analysis	  
 
In this preliminary analysis we compared the outcomes of different variables 
between a well controlled diabetic group (n=3) and a poorly controlled diabetic 
group (n=4) using two-sample t-test. The histological analysis in the well 
controlled diabetic group was performed on 2 samples, while the clinical analysis 
was performed on 3. The histological analysis and the clinical analysis were 
performed on all subjects (n=4) from the poorly controlled diabetic group. Each 
outcome was analyzed separately, including buccal and mesial ISQ values, 
insertion torques, mean bone marrow adipose surface area in mm², mean vital 
bone surface area in mm², mean blood vessel surface area in mm² and the mean 
number of blood vessels per mm² in each cohort. The ISQ values 
(Buccal/Mesial) were measured at baseline and at three month post implant 
placement. We compared the outcome at each time point and the change of 
outcome variable (Baseline – three month) between the two cohorts, separately. 
In addition, we compared the baseline and three month measurements for all 
patients using paired t-test. Significance was claimed for p-value < 0.05. The 
statistical test results for the ISQ intergroup comparison between the well 
controlled and the poorly controlled diabetic groups are shown in Table 7, with 
the mean and standard deviation (SD) for each outcome and for each cohort 
group. The statistical analysis for the histological differences between bone core 
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samples taken from each cohort are presented in Table 14. 
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 Parameters were calculated using the two sample t-test for each cohort group, 
the mean adipose tissue surface area in mm², mean bone surface area in mm², 
mean blood vessel surface area in mm² and mean number of blood vessels per 
mm². 
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4.	  Results	  
4.1	  Patient	  enrollment	  
 
Subject screening and enrollment is illustrated in Figure 2. A total of 32 patients 
were screened. However, 24 did not meet the inclusion criteria while 1 declined 
participation in the study. A total of 7 patients were enrolled into the study with 4 
were allocated to the poorly controlled diabetic group and 3 to the well 
controlled diabetic group according to individual baseline HbA1c values. No 
patients were lost during follow-up or excluded from the analysis. 
 
4.2	  Patient	  demographics	  of	  the	  study	  population	  (n=7)	  
 
Enrolled patient demographics of the study population are presented in Table 1. 
All patients were older than 58 years of age at the time of enrollment. Enrolled 
patients consisted of five Caucasians and two African Americans. Three 
aprticipants were females and four were males. All of the females were enrolled 
into the poorly controlled group while three of the males were enrolled to the 
well controlled group and one to the poorly controlled group. 
34	  	  
 
4.3	  Implant	  placement	  appointment	  recorded	  information	  
for	  each	  patient	  
 
During the implant placement appointment recorded information for each patient 
is shown in Table 2. All sites received a 4.1x10 implant. Bone core samples were 
obtained from all implant sites and ISQ values at implant placement ranged from 
80-86 on the mesial implant surfaces and 79-85 on the buccal surfaces. The 
maximum insertion torque recorded was 60 N.cm while the minimum was 45 
N.cm. No buccal or lingual dehiscence were present at the time of implant 
placement and hence none of the implants sites were grafted. 
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4.3.1	  Seven	  days	  post	  operative	  follow	  up	  
 
Adverse events, change in medical history and VAS scores were obtained at the 
seven days post operative follow up appointment for all patients are shown in 
Table 3. Patient 001 (poorly controlled) presented with angular chielitis while 
Patient 003 (poorly controlled) reported a urinary infection that was managed by 
his physician. Two patients presented with post operative pain 1 week following 
surgery. Patient 001 (poorly controlled) self reported pain levels equal to 4 
(moderate pain) while patient 007 (well controlled) reported pain levels equal to 
2 (mild pain) using the Visual Analogue Scale (VAS) that was given to them.  
 
  
4.3.2	  Fourteen	  days	  post	  operative	  follow	  up	  for	  all	  
patients	  
 
Adverse events, change in medical history and VAS scores at the fourteen days 
post operative follow up appointment for all patients are depicted in Table 4. No 
further adverse reactions or changes in medical history were reported by the 
patients. All participants expressed 0 out of 10 pain levels using the VAS system.  
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4.3.3	  Implant	  related	  outcomes	  at	  the	  three	  months	  post	  
implant	  placement	  appointment	  
 
Implant related outcomes at the 3 months post implant placement appointment 
are illustrated in table 5. None of the patients had any adverse reactions 
associated with the implant placement. Patient 004 (well controlled) was 
instructed by his physician to stop his anti-diabetic medication, which resulted 
with an increased HbA1c (11%). Overall, the mesial ISQ values ranged from 84-
87 while the buccal ISQ values ranged from 84-88. None of the implants 
presented with clinically visible mobility. At the three months time period with 
respect to the well controlled diabetic patients, the HbA1c values for patient 002 
stayed within the well controlled group’s inclusion criteria (5.8%<HbA1c≥7%) 
while patients 004 and 007 had elevated HbA1c% levels with 11.0% and 7.6% 
respectively.  
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4.3.4	  Three	  months	  post	  crown	  delivery	  appointment	  
 
Findings for adverse reactions, change in medical history, peri-implant probing 
depths and implant mobility at the three months post crown delivery are shown 
in Table 6. Four of the patients, exhibited peri-implant probing depths were 1-3 
mm. However, for patient 005 (poorly controlled) there was a single surface 
(Mesio-Buccal) that was positive for bleeding on probing with the overall 
probing depths ranged between 2-4 mm. None of the implants presented with 
any clinically diagnosed mobility at this time frame. All patients received a 
cement retained crown, yet information about patients 006 and 007 wasn’t 
included due to the fact that three months hadn’t passed since the crown delivery. 
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4.3.5	  ISQ	  intergroup	  comparison	  	  
 
ISQ intergroup comparison between the well controlled and the poorly controlled 
diabetic groups is shown in Table 7. Both study groups achieved favorable 
baseline (implant placement) and three months post placement mean ISQ values 
and insertion torques. The mean baseline buccal ISQ values for the well 
controlled group was 84.666 while 82.000 was recorded in the poorly controlled 
group. At three months post implant placement slightly higher mean ISQ values 
were recorded with 85.666 for the well controlled group and 85.250 for the 
poorly controlled group. The mean change in buccal ISQ values between 
baseline and at the three months appointment was 1.000 for the well controlled 
group and 3.250 for the poorly controlled group. 
The mean baseline mesial ISQ values for the well controlled group was 85.000 
while for the poorly controlled group a mean ISQ of 83.250 was recorded. At the 
three months post operative appointment the mean mesial ISQ values for the well 
controlled group was 85.333 while 85.500 for the poorly controlled group was 
recorded. The mean change in mesial ISQ values between baseline and the three 
months appointment was 0.333 for the well controlled group and 2.250 for the 
poorly controlled group.   
In both groups the implants were inserted with high mean insertion torques, 
56.666 N.cm for the well controlled group and 51.250 N.cm for the poorly 
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controlled group. There were no statistically significant differences (p>0.05) 
between the two study groups for any recorded parameter.  
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4.4	  Histology	  	  
4.4.1	  Hematoxylin	  and	  Eosin	  (H&E)	  staining	  of	  bone	  core	  samples	  
from	  a	  representative	  well	  controlled	  diabetic	  patient	  and	  from	  a	  
representative	  poorly	  controlled	  diabetic	  patient	  
 
Figure 3A depicts a sectioned bone core that has been stained with H&E and 
viewed at 20x magnification to represent a well controlled diabetic patient. The 
cut bone core section includes the bone surface area, the bone marrow and the 
sawdust (which is a consequence of bone harvesting with the trephine drill). This 
surface area was used for evaluation of the total cut bone core sectioned surface 
area for each patient in the well controlled diabetic group. Surface bone area with 
the bone marrow and sawdust removed from a well controlled diabetic patient is 
presented in Figure 3B. This sample was used for determination of the total bone 
surface area in cut sections harvested from well controlled diabetic patients. 
Surface bone marrow area from a well controlled diabetic representative is 
shown in Figure 3C. The cut sections were divided to 4 equal parts. These 
divided cut sections were used for the calculation of bone marrow surface area 
depicted as encircled in yellow color.  
Figure 4A represents the cut bone core section stained with H&E at a 20x 
magnification from a poorly controlled diabetic patient are presented in Figure 
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4A.  
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Similarly, to Figure 3A, the entire bone core cut section includes the bone 
surface area, bone marrow and sawdust. This surface area was used for 
evaluation of the total cut bone core sectioned surface area for each patient in the 
well controlled diabetic group. Surface bone area with the bone marrow and 
sawdust removed from a poorly controlled diabetic patient is presented in Figure 
4B. Determination of the total bone surface area in the cut sections from poorly 
controlled diabetics was done by removing the sawdust and areas identified as 
bone marrow. Surface bone marrow area from a poorly controlled diabetic is 
shown in Figure 4C. Again, the cut sections were divided to 4 equal parts. The 
divided cut sections were used for the calculation of bone marrow surface area as 
encircled in yellow color. Bone core section stained with Hematoxylin and Eosin 
from the well-controlled diabetic and poorly controlled diabetic groups are 
depicted in Figures 11 and 12.  
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4.4.2	  Factor	  VIII	  staining	  for	  blood	  vessel	  detection	  from	  a	  
representative	  well	  controlled	  diabetic	  patient	  and	  from	  a	  
representative	  	  poorly	  controlled	  diabetic	  patient	  
 
The bone core cut sections also underwent through immunohistochemistry with 
Factor VIII to identify blood vessels within the cut sections. A bone core cut 
section from a representative well controlled diabetic patient using 
immunohistochemistry with Factor VIII is depicted in Figure 5. Areas that 
stained positively with Factor VIII and exhibited a lumen like area were 
considered blood vessels and were encircled in yellow color. 
Similarly, bone core cut section from a representative poorly controlled diabetic 
patient using immunohistochemistry with Factor VIII is illustrated in Figure 6. 
Positively stained surfaces that exhibited a lumen like area were again 
considered blood vessels and encircled in yellow color. The number of blood 
vessels and blood vessel total surface area were calculated using the yellow 
encircled areas from each bone core cut section using 40x magnification. 
Immunohistochemistry using Factor VIII from the well controlled and poorly 
controlled diabetic samples are depicted in Figures 13 and 14. 
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4.4.3	  Bone	  core	  analysis	  
4.4.4	  Bone	  Surface	  Area	  in	  mm²	  
 
For the calculation of the Total bone surface area in each sample, was calculated 
subtracting values for bone marrow and sawdust. Hematoxylin & Eosin staining 
analysis of total bone surface area in mm² is presented in Table 8. These samples 
were divided into 4 equal parts that were analyzed individually and summed for 
determination of whole bone surface area in mm² from each sample. The total 
bone surface area from the well controlled group ranged from 7.33 mm² to 10.21 
mm² while in the poorly controlled group it ranged from 3.58 mm² to 12.32 mm². 
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4.4.5	  Area	  of	  Bone	  Marrow	  in	  mm²	  
 
Bone marrow surface area was identified using the bone core samples stained 
with Hematoxylin & Eosin. Areas that were recognized as bone and sawdust 
were not included in the bone marrow surface area calculation. All areas that 
included bone marrow were encircled in yellow and the total surface area was 
calculated in mm². Hematoxylin & Eosin staining analysis of total bone marrow 
surface in mm² is shown in Table 9. Briefly, the 2 well controlled group samples 
were relatively similar with 0.77 mm² and 0.79 mm² of total bone marrow 
surface area. The poorly controlled group showed higher variability with sample 
006 having 0.00 mm² bone marrow surface area compared to sample 001 with 
4.57 mm². When looking at the cancellous 25% area, it is noteworthy that no 
area of fatty bone marrow in mm² (0.00) for samples 003, 005, 006 (poorly 
controlled) and for sample 004 (well controlled) was found. Sample 001 was 
shown to have a larger bone marrow surface area in mm² than all of the other 
samples combined regardless of their group allocation. 
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4.4.6	  Total	  live	  tissue	  area	  in	  mm²	  
 
Factor VIII histomorphometrical analysis of total live tissue area in mm² is 
presented in Table 10. Using 40x magnification, the total area of live tissue in 
mm² was calculated including the bone marrow, bone and blood vessels surface 
area. Sawdust was removed for this analysis. The results of this 
histomorphometrical analysis is illustrated in Table 10. The well controlled 
group total surface area in mm² ranged from 12.04 to 13.22, while in the poorly 
controlled group it ranged from 4.79 mm² to 13.34 mm².  
 
4.4.7	  Total	  Blood	  Vessel	  Surface	  Area	  in	  mm²	  
 
Slides stained with the immunohistochemistry technique for endothelial cells 
detection (Factor VIII) were examined under 40x magnification. Areas that were 
stained positively with Factor VIII and presented with a lumen like area were 
considered as blood vessels and encircled in yellow. Factor VIII 
histomorphometrical analysis of total blood vessel surface area in mm² is shown 
in Table 11. In the well controlled diabetic group, sample 002 had 0.157 mm² 
blood vessel surface area while sample 004 had 0.632 mm². The poorly 
controlled diabetic group total blood vessel surface area ranged from 0.104 mm² 
to 0.290 mm². Surprisingly, in sample 005 (poorly controlled) blood vessels were 
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identified only in the top cortical quadrant.  
 
4.4.8	  Number	  of	  Blood	  Vessels	  per	  sample	  &	  percent	  of	  
blood	  vessel	  total	  surface	  area	  
 
The number of blood vessels per sample and the percent of blood vessel total 
surface area for each sample are presented in Table 12. In the well controlled 
diabetic group, sample 002 had 32 blood vessels per sample, while sample 004 
had 151. For the poorly controlled group the number of blood vessels per sample 
ranged from 35 to 56. For the whole area of blood vessel in mm², the well 
controlled diabetic group ranged from 0.157 mm² to 0.632 mm² while the poorly 
controlled diabetic group ranged from 0.117 mm² to 0.290 mm². Also, the 
percent of total blood vessel surface area is shown in Table 12. The percent of 
total blood vessel surface area was calculated by dividing the whole area of 
blood vessels mm² by the whole live tissue area in mm² multiplying by a hundred 
for each sample. The well controlled diabetic group ranged from 1.308 % to 
4.785 % of percent blood vessels area while the poorly controlled diabetic group 
ranged from 0.779% to 3.478%.  
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4.4.9	  Number	  of	  Blood	  Vessels	  per	  mm²	  for	  each	  sample	  
 
The number of blood vessels per mm² for each sample is presented in Table 13. 
For calculation of the number of blood vessels per mm² the blood vessels were 
manually counted and divided by the total bone surface area in mm² for each 
specimen. The well controlled group ranged from 3.134 blood vessels per mm² 
to 20.600, while in the poorly controlled group the results ranged from 2.840 to 
13.128 blood vessels per mm². 
 
4.4.9.1	  Histological	  differences	  between	  the	  bone	  core	  
samples	  that	  were	  taken	  from	  the	  well	  controlled	  diabetic	  
group	  and	  the	  poorly	  controlled	  diabetic	  group.	  
  
Histological differences between the bone core samples that were taken from the 
well controlled diabetic group and the poorly controlled diabetic group are 
presented in Table 14. The analyzed histological parameters include the mean 
Adipose Tissue/Sample mm², mean Bone Surface Area/ Sample mm², Mean 
Blood vessel surface area mm² and Mean Number of Blood Vessels per mm². 
Amongst the compared parameters, mean Adipose Tissue/Sample mm² was 
shown to be 0.780 mm² in the well controlled diabetic group compared to 1.350 
mm² in the poorly controlled diabetic group.  
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The standard deviation in the well controlled diabetic group was low (0.014) 
while the poorly controlled diabetic group had a higher standard deviation 
(2.169). The difference between the two groups was not found to be statistically 
significant (p>0.05); but a trend was still observed. The poorly controlled 
diabetic group demonstrated almost twice the amount of total adipose tissue 
surface area of 1.35 mm² as compared to 0.78 mm² in the well controlled diabetic 
group as illustrated.  
Another compared parameter was the mean Bone Surface Area/Sample mm². 
The mean bone surface area in mm² of cut tissue samples taken from the well 
controlled diabetic group and the poorly controlled diabetic group can be seen in 
Table 14. The well controlled diabetic group presented with 8.770 mm² 
(SD=2.036) while the poorly controlled diabetic group had 7.220 mm² 
(SD=3.666). The difference between the two groups was not found to be 
statistically significant (p>0.05).  
 
The mean blood vessel surface area in mm² calculated from bone core samples 
taken from well controlled and poorly controlled diabetic patients is shown in 
Table 14. The mean Area Blood Vessels/Sample mm² in each cohort was 
determined for the well controlled diabetic group to be 0.395 mm² (SD=0.335) 
compared to 0.159 mm² (0.088) in the poorly controlled diabetic group. Again, 
the difference was not found to be statistically significant (p>0.05), yet a trend 
can be observed with more than double the Area of Blood Vessels/Sample mm² 
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in the well controlled diabetic group than the poorly controlled diabetic group. 
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The mean number of blood vessels per mm² was calculated from bone core 
samples taken from well controlled and poorly controlled diabetic patients is 
shown in Table 14. The well controlled group had 11.867 blood vessels per mm² 
compared with 8.229 per mm² in the poorly controlled group. The standard 
deviation in the well controlled diabetic group was 12.350 while the poorly 
controlled diabetic group had a relatively smaller standard deviation of 4.212. 
The difference between the two cohorts was not found to be statistically 
significant with p>0.05.  
 
The mean bone marrow tissue surface area in mm² was calculated from cut bone 
core samples taken from well controlled (0.700 mm²) and poorly controlled (1.06 
mm²) diabetic groups are illustrated in Figure 7. The mean Bone Surface 
Area/Sample mm² calculated from bone core samples taken from well controlled 
(8.770) and poorly controlled diabetic patients (7.220) is shown in Figure 8. 
Mean blood vessel surface area of each cohort in mm² calculated from bone core 
samples taken from well controlled and poorly controlled diabetic patients is 
presented in Figure 9. The mean number of blood vessels per mm² in each cohort 
group calculated from bone core samples taken from well controlled (11.85) and 
poorly controlled (8.17) diabetic patients is depicted in Figure 10. 
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5.	  Discussion	  
 
It is well established that Type II DM may result in accumulation of AGEs, 
which compromises the bone matrix properties due to defective collagen 
production. The AGEs have been found to alter osteoblastic proliferation and 
increase osteoclastic bone resorption [47]. In a recent review, it was shown that 
Type II DM mice presented with a significantly lower Bone to Implant Contact 
when compared with healthy mice. It was also found that the majority of 
alterations were found to be in the cortical bone area while the cancellous bone 
was less affected by these alterations [48]. In a more recent study, whereby Type 
II DM patients who underwent limb amputation due to critical ischemia, it was 
exhibited that Type II DM bone marrow alterations that resulted in decreased 
hematopoietic tissue [10,49]. The authors suggest that this could lead to an 
increase in bone marrow adiposity and that these changes were found to be 
inversely associated with decreased distal femur bone volumes in animals. An 
earlier histomorophometric study found a direct association between increased 
bone marrow adiposity and decreased osteoblastic activity in 51 human iliac 
crest biopsies [50]. Decreased osteoblastic activity had been previously 
associated with decreased bone formation and mineral apposition [10,11,22]. 
Spinetti et al. used histomorphometric evaluation of bone marrow adiposity in 
patients that underwent hip replacement [49]. They concluded that the adipose 
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tissue fraction difference between the healthy control group and the Type II DM 
group was statistically significant (p<0.001). 
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In this study, we also attempted to compare the adipose tissue surface area in 
mm² of well controlled and in poorly controlled Type II DM patients. However, 
our findings didn’t reach statistical significance with a relatively small sample 
size of evaluated subjects. Nevertheless, a trend was present with almost double 
adipose surface area in the poorly controlled group compared to the well 
controlled group. A large standard deviation (2.169) in the poorly controlled 
group was observed which was not seen in the well controlled group (0.014). 
The higher standard deviation must be interpreted carefully due to the small 
sample size in this study.  
 
Our investigation also evaluated blood vessel density. Stabley and co-
investigators found that Type II DM rats might have altered blood flow in their 
marrow when compared to healthy rats [51]. The investigators concluded that 
these alterations may eventually lead to osteopenia. Teraa et al. noted in a human 
histology study of patients with critical limb ischemia, that the blood vessel 
density was lower in patients with Type II DM (32.3 microvessels/mm²) 
compared to healthy controls (40.2 microvessels/mm²), the difference between 
the two groups was found to be statistically significant (p=0.01) [52]. Spinetti 
compared bone biopsies for blood vessel density in patients with Type II DM 
with non-diabetic healthy controls undergoing a full hip replacement procedure 
[35].  
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Histomorphometry using CD31 and Factor VIII were performed on the hip bone 
samples. A total of 49 patients were enrolled into the control non-diabetic group 
and 10 patients into the Type II DM group. It was found that Type II DM 
patients presented with 11.3 capillaries per mm² while healthy individuals 
presented with 25.3 capillaries per mm². The difference was statistically 
significant with a relatively small standard deviation (2.4 and 3.1, respectively). 
The authors concluded that a statistically significant decrease of capillary density 
was observed and that the dependent microvascular variables included diabetes 
mellitus duration and fasting glucose levels. In this study, the difference between 
the blood vessel density in the well controlled and poorly controlled Type II DM 
groups was not found to be statistically significant (p>0.05). Nevertheless, a 
trend can be observed with 11.867 blood vessels per mm² in the well controlled 
diabetic group and 8.229 per mm² in the poorly controlled diabetic group. Both 
the Teraa et al. [34] and Spinetti et al. [35] studies have presented with a 
significantly higher number of blood vessels per mm² when compared to the 
results of this study. The differences might be attributed to the inherent 
characteristics of the mandibular bone when compared to long bones (hip/limbs) 
and, perhaps as elucidated by Spinetti, by the diabetic duration and overall 
fasting glucose levels.  
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Regardless of the quantitative difference between the two diabetic groups, all 
implants were successfully placed with a high insertion torque and ISQ values. A 
healing abutment was secured in a non-submerged healing site allowing for a 
standardized implant placement protocol. At the 7 days post operative 
appointment minimal adverse reactions were recorded with only angular cheilitis 
and a urinary infection affecting two patients. Minimal post operative pain was 
noted according to VAS scale was communicated to the investigators. At the 14 
days post-operative appointment, no adverse reactions were recorded and no post 
operative pain was reported by the patients. It is important to point out that one 
patient was instructed by their physician to stop taking their diabetes medication, 
consequently their HbA1c levels increased up to 11% at the 3 months post 
operative appointment. Surprisingly, the change in HbA1c didn’t affect implant 
integration or peri-implant bone levels and probing depths. None of the patients 
presented with positive bleeding on probing in the peri-implant gingival sulcus 
except for patient 005 who was in the poorly controlled diabetic group. 
 
Because of the limited number of patients evaluated, the reported results should 
be interpreted with caution. Significant efforts were taken to initiate this 
investigation and enroll the initial patients by the investigators. With continued 
enrollment of a greater number of patients the resulting data may validate our 
conclusions.  
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6.	  Conclusions	  	  	  
Within the limitation of this study it can be concluded that: 
 
1. The well controlled diabetic group (5.8%<HbA1c≥7%) presented with a mean 
of 11.867  
    blood vessels per mm² as compared with 8.229 per mm² in the poorly 
controlled diabetic  
    (7.5% <HbA1c>10%) group. 
 
2. When comparing the mean bone marrow surface area it was found that the 
poorly  
    controlled diabetic group (7.5% <HbA1c>10%) presented with 1.06 mm² 
compared to  
    0.70 mm² in the well controlled diabetic group (5.8%<HbA1c≥7%). 
 
3. Within the first 6 months after implant placement it can be concluded that 
hydrophilic  
    TiZr implant surfaces (Roxolid®) yielded similar early implant stability,  
    survival and success rates in poorly and well controlled Type II DM 
individuals    
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    whereby all implants were successful according to the criteria of Karoussis et 
al [20]. 
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Figures	  
 
Figure 1. ACE trephine system assembly for bone harvesting. 
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Figure 2. Patient screening and enrollment  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   Subjects included in clinical analysis (n=3) Subjects included in histological analysis (n=2) 
 	  	  
Subjects included in analysis (n=4) 
 
Analysis	  
Lost to follow-up (n=0) 
Discontinued intervention (n=0) 
Lost to follow-up (n=0) 
Discontinued intervention (n=0) 
Follow-­‐Up	  
Well controlled 
diabetes (5.8-7%) (n=3) 	  	  
Poorly controlled diabetes 
(7.5-10%) (n=4) 	  
Allocation	  
Enrolled subjects (n=7) 
♦	  	  	  Not meeting inclusion 
criteria (n=24) 
♦	  	  	  Declined to participate (n=1) 
 
Enrollment	   Screened for eligibility (n=32) 
Figure	  1A.	  Unassembled	  ACE	  trephine	  system.	  Figure	  1B.	  Assembly	  of	  the	  three	  piece	  ACE	  trephine	  system	  for	  bone	  core	  retrieval.	  Figure	  1C.	  After	  retrieval	  of	  the	  bone	  core	  sample	  a	  fourth	  piece	  is	  introduced	  to	  gently	  push	  the	  bone	  core	  out	  of	  the	  trephine.	  Figure	  1D.	  The	  bone	  core	  sample	  removed	  from	  the	  three	  piece	  ACE	  trephine	  system.	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Figure	  3.	  Stained	  bone	  core	  section	  stained	  with	  Hematoxylin	  and	  Eosin	  from	  a	  well	  controlled	  diabetic	  patient	  (002)	  in	  20x	  magnification.  
Figure 3A Represents the total bone core (including bone surface area, bone 
marrow and sawdust). Figure 3B Bone marrow and sawdust are removed and 
only the bone surface area is present. Figure 3C The bone marrow surface area 
encircled in yellow. 
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Figure	  4.	  Stained	  bone	  core	  section	  stained	  with	  Hematoxylin	  and	  Eosin	  from	  a	  poorly	  controlled	  diabetic	  patient	  (002)	  in	  20x	  magnification. Figure 
4A represents the total bone core (including bone surface area, bone marrow and 
sawdust). Figure 4B shows the bone surface area only (bone marrow and the 
sawdust were removed). Figure 4C illustrates the bone marrow surface area 
(encircled in yellow). 
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Figure 5.	  Using	  immunohistochemistry	  (Factor	  VIII)	  to	  specifically	  identify	  endothelial	  cells	  from	  sample	  002	  (Well	  controlled	  diabetic	  group).	  Positively	  stained	  cells	  that	  present	  with	  a	  lumen	  like	  areas	  were	  identified	  as	  blood	  vessels	  and	  encircled	  in	  yellow.  
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Figure 6.	  Using	  immunohistochemistry	  (Factor	  VIII)	  to	  specifically	  identify	  endothelial	  cells	  from	  sample	  001	  (Poorly	  controlled	  diabetic	  group).	  Positively	  stained	  cells	  that	  present	  with	  a	  lumen	  like	  areas	  were	  identified	  as	  blood	  vessels	  and	  encircled	  in	  yellow. 	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Figure 7. Mean bone marrow surface area in mm² calculated from bone core 
samples  
                taken from well controlled and poorly controlled diabetic patients. 
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Figure 8. Mean bone surface area in mm² calculated from bone core samples 
taken from  
                well controlled and poorly controlled diabetic patients. 
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Figure 9. Mean blood vessel surface area of each cohort in mm² calculated from 
bone core samples taken from well controlled and poorly controlled diabetic 
patients. 
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Figure	  10.	  Mean number of blood vessel per mm² calculated from bone core 
samples  
                   taken from well controlled and poorly controlled diabetic patients. 
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Figure	  11.	  Stained	  bone	  core	  section	  stained	  with	  Hematoxylin	  and	  Eosin	  from	  the	  well-­‐controlled	  diabetic	  group	  in	  20x	  magnification.  
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004 A and 004 B (Sample fractured during harvesting) 
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Figure	  12.	  Stained	  bone	  core	  section	  stained	  with	  Hematoxylin	  and	  Eosin	  from	  the	  poorly-­‐controlled	  diabetic	  group	  in	  20x	  magnification.	  	  001	  
	  003	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Figure 13. Immunohistochemistry using Factor VIII from the well controlled 
diabetic      
                   group 40x magnification. 
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Figure 14. Immunohistochemistry using Factor VIII from the poorly controlled 
diabetic  
                  group 40x magnification. 
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Tables	  	  
Table 1. Patient demographics of the study population (n=7). 
Patient ID Baseline HbA1c Cohort allocation Age Implant site Ethnicity* Race Gender 
004 6.9% Well controlled 68 20 NHL  Caucasian Male 
002 6.3% Well controlled 58 30 NHL  Caucasian Male 
007 7.0% Well Controlled 64 29 NHL  African American Male 
        
003 9.2% Poorly controlled 68 20 NHL  Caucasian Male 
001 8.1% Poorly controlled 60 19 NHL  Caucasian Female 
005 8.5% Poorly controlled 64 30 NHL  Caucasian Female 
006 8.7% Poorly controlled 72 28 NHL  African American Female 
007 7.0% Well Controlled 64 29 NHL  African American Male 
* NHL: Non-Hispanic or Latin 
96	  	  
	  
Table 2. Implant placement appointment recorded information. 
Patient 
ID and 
study 
group 
Implant 
placed 
Bone core 
obtained 
ISQ values 
(Triplicate 
average)  
Maximum 
insertion 
torque 
(N.cm) 
Buccal 
dehiscence 
present  
(Yes/No) 
Lingual 
dehiscence 
present 
(Yes/No) 
Implant 
site 
grafted  
(Yes/No) 
004 
WC 
4.1x10  Yes Mesial 84 
Buccal 84 
60 No No No 
002 
WC 
4.1x10 Yes Mesial 86 
Buccal 85 
50 No No No 
007 
WC 
4.1x10 Yes Mesial 85 
Buccal 85 
60 No No No 
        
003 
PC 
4.1x10 Yes Mesial 80 
Buccal 82 
50 No No No 
001 
PC 
4.1x10 Yes Mesial 85 
Buccal 85 
50 No No No 
005 
PC 
4.1x10 Yes Mesial 82 
Buccal 82 
45 No No No 
006 
PC 
4.1x10 Yes Mesial 86 
Buccal 79 
60 No No No 
	  WC-­‐	  Well	  controlled	  group;	  PC	  –Poorly	  controlled	  group	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Table 3. Adverse events, change in medical history and VAS scores at the seven 
days post operative follow up appointment. 
Patient ID and 
study group 
Adverse events/ 
Change in medical 
history 
VASW score (0-10) 
004 WC No 0 
002 WC No 0 
007 WC No 2 
   
003 PC Urinary infection 0 
001 PC Angular chielitis 4 
005 PC No 0 
006 PC No 0 
 WC- Well controlled group; PC- Poorly controlled group 
WVAS-Visual Analogue scores  
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Table 4. Adverse events, change in medical history and VAS scores at the 
fourteen days post operative follow up appointment for all patients. 
Patient ID and 
study group 
Adverse events/ 
Change in medical 
history 
VASW score (0-10) 
004 WC No 0 
002 WC No 0 
007 WC No 0 
   
003 PC No 0 
001 PC No 0 
005 PC No 0 
006 PC No 0 
 WC- Well controlled group; PC- Poorly controlled group 
WVAS-Visual Analogue scores 
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Table 5. Implant related outcomes at the 3 months post implant placement 
appointment. 
Patient 
ID and 
study 
group  
Adverse 
reaction/ 
Change in 
medical 
history 
ISQ 
values 
(Triplicate 
average) 
Implant 
mobility 
3 months 
HbA1c 
% 
004 WC Instructed to 
stop DM 
medication 
Mesial 84 
Buccal 84 
No 11.0 % 
002 WC No Mesial 87 
Buccal 88 
No 6.4 % 
007 WC No Mesial 85 
Buccal 85 
No 7.6 % 
     
003 PC No Mesial 85 
Buccal 85 
No 7.7 % 
001 PC No Mesial 85 
Buccal 85 
No 9.0 % 
005 PC No Mesial 85 
Buccal 85 
No 8.6 % 
006 PC No Mesial 87 
Buccal 86 
No 8.8 % 
  WC- Well controlled group; PC- Poorly controlled group 
100	  	  
Table 6. Adverse reactions, change in medical history, peri-implant probing 
depths and implant mobility at the three months post crown delivery appointment 
Patient 
ID and 
study 
group 
Adverse 
reaction/Change 
in medical 
history 
Peri-implant 
probing 
depth in mm 
(MB, B, DB, 
ML, L, DL) 
**u 
Implant 
mobility 
(Yes/No) 
004 
WC 
Placed on 
metformin again 
4(+),3,4,4,2,3 No 
002 
WC 
No 1,3,1,2,3,2 No 
003 PC No 1,2,3,2,3,3 No 
007 
WC 
N/A N/A N/A 
    
001 PC No 2,1,2,1,1,1 No 
005 PC No 2,2,3,3,2,2 No 
006 PC N/A N/A  N/A 
007 
WC 
N/A N/A N/A 
   WC- Well controlled group; PC- Poorly controlled group  
**     Probing depth location on the implant: MB- Mesiobuccal, B- Buccal, DB- Distobuccal, 
ML-  
         Mesiolingual, L- Lingual, DL- Distolingual 
 +      Represents areas with positive bleeding on probing 
u     N/A – Data not available 
101	  	  
Table 7. ISQ intergroup comparison between the well controlled and the poorly  
               controlled diabetic groups 
*ISQ	  values	  and	  insertion	  torque	  comparison	  between	  the	  well	  controlled	  diabetic	  group	  and	  poorly	  controlled	  diabetic	  group	  were	  calculated	  using	  two	  sample	  T-­‐test,	  p≤0.05	  was	  considered	  statistically	  significant.	  	  	  	  	  
Factor 
ISQ or Insertion 
torque 
Well-Controlled group 
(5.8%<HbA1c≥7%) 
n=3 
Poorly-Controlled group 
(7.5%<HbA1c>10%) 
n=4 
P-value* 
Baseline ISQ 
Buccal, mean (SD) 
 
84.666 (0.577) 
 
82.000 (2.440) 
 
0.13 
3 Months ISQ 
Buccal, Mean (SD) 
 
85.666 (2.081) 
 
85.250 (0.500) 
 
0.71 
ISQ Buccal change, 
mean (SD) 
 
1.000 (1.732) 
 
3.250 (2.872) 
 
0.29 
Baseline ISQ 
Mesial, mean (SD) 
 
85.000 (1.000) 
 
83.250 (2.753) 
 
0.35 
3 Months ISQ 
mesial, mean (SD) 
 
85.333 (1.527) 
 
85.500 (1.000) 
 
0.87 
ISQ Mesial change, 
mean (SD) 
 
0.333 (0.577) 
 
2.250 (2.217) 
 
0.21 
Insertion Torque 
N.cm, mean (SD) 
 
56.666 (5.773) 
 
51.250 (6.291) 
 
0.30 
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Table	  8.	  Hematoxylin	  &	  Eosin	  staining	  analysis	  of	  total	  bone	  surface	  area	  in	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  mm² 
 Sample ID 
And study 
group 
 Area of bone (mm²) 
Whole 
bone 
surface 
area 
(mm²) 
 
Bottom 
cancellous 
25% 
lower middle  
25% 
upper middle 
25% 
Top 
cortical 
25% 
004 WC 0.00 0.90 2.65 2.77 7.33 
002 WC 2.55 1.95 3.12 2.59 10.21 
      
003 PC 0.00 0.00 3.18 3.33 6.51 
001 PC 0.80 1.99 1.39 2.29 6.47 
005 PC 0.00 0.00 0.00 3.58 3.58 
006 PC 2.68 3.32 3.54 2.78 12.32 
    PC- Poorly Controlled group (HbA1c 7.5-10.0%); WC- Well controlled group 5.8-7.0% 
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Table 9. Hematoxylin & Eosin staining analysis of adjusted total bone marrow surface 
in mm² 
   PC- Poorly Controlled group (HbA1c 7.5-10.0%); WC- Well controlled group 5.8-7.0% 	  	  	  	  
  Sample ID 
And study 
group 
 Area of bone marrow (mm²) 
Whole 
bone 
marrow 
surface 
area 
(mm²) 
 
cancellous 
25% 
lower middle  
25% 
upper middle 
25% 
cortical 
25% 
004 WC 0.00 0.03 0.18 0.57 0.73 
002 WC 0.07 0.20 0.41 0.08 0.67 
      
003 PC 0.00 0.00 0.66 0.06 0.58 
001 PC 0.45 1.51 1.66 0.96 3.57 
005 PC 0.00 0.00 0.00 0.11 0.10 
006 PC 0.00 0.00 0.00 0.00 0.00 
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Table	  10. Factor VIII histomorphometrical analysis of adjusted total live tissue  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  area in mm². 
 Sample ID 
And study 
group 
 Area of live tissue  (mm²) Whole 
live tissue 
area 
(mm²) 
 
Cancellous 
25% 
Lower 
middle  
25% 
Upper 
middle 
25% 
Cortical 
25% 
004 WC 0.00 1.87 5.6 5.75 12.13 
002 WC 2.91 3.07 3.26 2.81 10.2 
      
003 PC 0.00 0.00 4.01 4.35 6.67 
001 PC 1.97 3.71 3.23 3.18 9.45 
005 PC 0.00 0.00 0.00 4.79 4.2 
006 PC 2.70 2.94 3.87 3.83 9.4 
   PC- Poorly Controlled group (HbA1c 7.5-10.0%); WC- Well controlled group 5.8-7.0% 
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Table 11. Factor VIII histomorphometrical analysis of adjusted total blood 
vessel surface area in mm². 
Sample ID 
And study 
group 
 Area of blood vessels (mm²) Whole 
area of 
blood 
vessels 
(mm²) 
 
cancellous 
25% 
lower 
middle  
25% 
upper 
middle 
25% 
cortical 
25% 
004 WC 0.000 0.177 0.275 0.179 0.582 
002 WC 0.024 0.026 0.051 0.055 0.137 
      
003 PC 0.000 0.000 0.165 0.125 0.240 
001 PC 0.001 0.022 0.042 0.050 0.097 
005 PC 0.000 0.000 0.000 0.125 0.124 
006 PC 0.062 0.024 0.012 0.004 0.074 
   PC- Poorly Controlled group (HbA1c 7.5-10.0%); WC- Well controlled group 5.8-7.0% 
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Table 12. Number of blood vessels per sample and percent of blood vessel total  
                 surface area manually calculated from Factor VIII           
                 immunohistochemistry stained samples. 
 
Sample ID And 
study group 
 
Number of Blood 
Vessels per sample 
Whole area of 
blood vessels mm² 
Adjuste
d live 
tissue 
area in 
mm² 
Adjuste
d 
percent 
of blood 
vessel 
surface 
area 
004 WC 151 0.632 12.13 4.79 % 
002 WC 32 0.157 10.2 1.34 % 
     
003 PC 54 0.290 6.67 3.50 % 
001 PC 56 0.117 9.45 1.02 % 
005 PC 47 0.125 4.2 2.95 % 
006 PC 35 0.104 9.4 0.78 % 
   PC- Poorly Controlled group (HbA1c 7.5-10.0%); WC- Well controlled group 5.8-7.0% 
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Table 13. Adjusted number of blood vessels per mm² for each sample. 
Sample ID And study group 
 
Number of Blood Vessels per mm² 
004 WC 11.4 
002 WC 2.6 
  
003 PC 6.4 
001 PC 4.6 
005 PC 9.7 
006 PC 2.6 
   PC- Poorly Controlled group (HbA1c 7.5-10.0%); WC- Well controlled group 5.8-7.0% 
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Table 14. Histological differences between bone core samples taken from the  
                    well controlled diabetic group and the poorly controlled diabetic group 
 
Parameters Well 
controlled 
diabetes 
group 
(n=2) 
Poorly 
controlled 
diabetes group 
(n=4) 
P-value  
Adipose 
Tissue/Sample 
mm², mean (SD) 
 
0.780 
(0.014) 
 
1.350 (2.169) 
 
0.74 
Bone Surface 
Area/ Sample 
mm², mean (SD) 
 
8.770 
(2.036) 
 
7.220 (3.666) 
 
0.62 
Blood vessels 
surface area/ 
Sample mm², 
mean (SD) 
 
0.395 
(0.335) 
 
0.159 (0.088) 
 
0.21 
Mean Number of 
Blood Vessels per 
mm² (SD) 
 
11.867 mm² 
(12.350) 
 
8.229 mm² 
(4.212) 
 
0.58 
Comparisons between adipose tissue/sample mm², bone surface area/sample 
mm², area of blood vessel/sample mm² and mean number of blood vessels per 
mm² of bone core samples from well controlled diabetic patients and poorly 
controlled diabetic patients were calculated using two sample t-test, p≤0.05	  was	  considered	  statistically	  significant. 	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Table	  15.	  Bone	  core	  histology	  analysis	  adjustment	  Sample	  ID	  and	  study	  group	  
Whole	  tissue	  area	  in	  mm² 	   Bone	  dust	  surface	  area	  in	  mm²	  
Percentage	  of	  bone	  dust	  from	  samples	  004	  WC	   14.42	   1.2	   8.3	  002	  WC	   14.23	   2.19	   15.3	  	   	   	   	  003	  PC	   10.49	   2.13	   20.3	  001	  PC	   15.49	   3.4	   21.9	  005	  PC	   5.47	   0.68	   12.4	  006	  PC	   19.07	   5.73	   30	  
 
 
